Barinthus Biotherapeutics Plc ADR
(BRNS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -55,355 | -40,784 | -19,658 | -61,183 | -40,592 |
| Depreciation Amortization | 4,936 | 4,035 | 2,034 | 5,800 | 4,372 |
| Income taxes - deferred | -118 | -47 | -22 | -44 | -47 |
| Accounts payable and accrued liabilities | -1,854 | -813 | -1,155 | 898 | 1,358 |
| Other Working Capital | -3,797 | -2,335 | -137 | 2,601 | -12,551 |
| Other Operating Activity | 12,451 | 6,933 | 4,036 | 22,988 | 5,434 |
| Operating Cash Flow | $-43,737 | $-33,011 | $-14,902 | $-28,940 | $-42,026 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 414 | -37 | -5 | -892 | -614 |
| Investing Cash Flow | $414 | $-37 | $-5 | $-892 | $-614 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2 | 2 | 2 | 2,163 | 1,326 |
| Financing Cash Flow | $2 | $2 | $2 | $2,163 | $1,326 |
| Exchange Rate Effect | 6,595 | 8,430 | 3,084 | -2,021 | 5,326 |
| Beginning Cash Position | 112,400 | 112,400 | 112,400 | 142,090 | 142,090 |
| End Cash Position | 75,674 | 87,784 | 100,579 | 112,400 | 106,102 |
| Net Cash Flow | $-36,726 | $-24,616 | $-11,821 | $-29,690 | $-35,988 |
| Free Cash Flow | |||||
| Operating Cash Flow | -43,737 | -33,011 | -14,902 | -28,940 | -42,026 |
| Capital Expenditure | -37 | -37 | -5 | -892 | -614 |
| Free Cash Flow | -43,774 | -33,048 | -14,907 | -29,832 | -42,640 |